REGISTERED NUMBER: |
Unaudited Financial Statements |
for the Period 1 July 2023 to 31 December 2023 |
for |
Particle Therapeutics Limited |
REGISTERED NUMBER: |
Unaudited Financial Statements |
for the Period 1 July 2023 to 31 December 2023 |
for |
Particle Therapeutics Limited |
Particle Therapeutics Limited (Registered number: 05613862) |
Contents of the Financial Statements |
for the Period 1 July 2023 to 31 December 2023 |
Page |
Company Information | 1 |
Balance Sheet | 2 |
Notes to the Financial Statements | 3 |
Particle Therapeutics Limited |
Company Information |
for the Period 1 July 2023 to 31 December 2023 |
DIRECTORS: |
SECRETARY: |
REGISTERED OFFICE: |
REGISTERED NUMBER: |
ACCOUNTANTS: |
10 The Green |
Cheddington |
Buckinghamshire |
LU7 0RJ |
Particle Therapeutics Limited (Registered number: 05613862) |
Balance Sheet |
31 December 2023 |
31.12.23 | 30.6.23 |
Notes | £ | £ |
CURRENT ASSETS |
Investments | 4 |
Cash at bank |
CREDITORS |
Amounts falling due within one year | 5 |
NET CURRENT LIABILITIES | ( |
) | ( |
) |
TOTAL ASSETS LESS CURRENT LIABILITIES |
( |
) |
( |
) |
CAPITAL AND RESERVES |
Called up share capital |
Share premium |
Retained earnings | ( |
) | ( |
) |
( |
) | ( |
) |
The directors acknowledge their responsibilities for: |
(a) | ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and |
(b) | preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company. |
In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered. |
The financial statements were approved by the Board of Directors and authorised for issue on |
Particle Therapeutics Limited (Registered number: 05613862) |
Notes to the Financial Statements |
for the Period 1 July 2023 to 31 December 2023 |
1. | STATUTORY INFORMATION |
Particle Therapeutics Limited is a |
The Company's principal activity is the holding of a minority investment in a Canadian company (Particle Vaccine Canada Limited) that is developing technology for needle-free delivery of pharmaceutical compounds in human applications. The company retains the right to apply such technology in animal applications and will continue to monitor and explore opportunities to do so. |
2. | ACCOUNTING POLICIES |
Basis of preparing the financial statements |
Taxation |
Taxation for the period comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity. |
Current or deferred taxation assets and liabilities are not discounted. |
Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date. |
Deferred tax |
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date. |
Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the period end and that are expected to apply to the reversal of the timing difference. |
Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. |
Research and development |
Expenditure on research and development is written off in the year in which it is incurred. |
Going concern |
The directors believe that sufficient funding will continue to be provided to meet the operating costs of the company for a period of at least 12 months from the approval of these financial statements. |
On this basis the directors are satisfied as to the going concern status of the company. |
Valuation of investments |
Investments in unlisted company shares are stated at historic cost less impairment as there is no market value available. |
3. | EMPLOYEES AND DIRECTORS |
The average number of employees during the period was NIL (2023 - NIL). |
Particle Therapeutics Limited (Registered number: 05613862) |
Notes to the Financial Statements - continued |
for the Period 1 July 2023 to 31 December 2023 |
4. | CURRENT ASSET INVESTMENTS |
31.12.23 | 30.6.23 |
£ | £ |
Unlisted investments | 81,455 | 52,081 |
5. | CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |
31.12.23 | 30.6.23 |
£ | £ |
Other creditors |
6. | RELATED PARTY DISCLOSURES |
At the year end the company owed the following shareholders the amounts listed below which are included in creditors:amounts falling due within one year. |
31-12-23 30-6-23 |
£ £ |
M Rushton Turner 320,155 290,781 |
7. | ULTIMATE CONTROLLING PARTY |
The controlling party is J M Rushton -Turner. |